Tilray Medical Supports New Clinical Trial to Study Medical
Cannabis in Glioblastoma Cancer Treatment
Tilray Medical, a division of Tilray Brands, Inc. ("Tilray" or the
"Company") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical
cannabis, empowering the therapeutic alliance between patients and
healthcare practitioners to make informed individualized health
decisions, transforming healthcare, today announced their
contribution to an independent clinical trial to research the
efficacy of medical cannabis as a treatment for glioblastoma, a
severe form of brain cancer. The clinical trial will be conducted
in Spain, recruiting 30 patients from eight specialized
neuro-oncology medical sites, in partnership with renowned
scientists from the Spanish Research Group of Neuro-Oncology
(GEINO) and the Complutense University of Madrid, with Tilray
Medical providing the pharmaceutical-grade medical cannabis for the
trial (THC/CBD 1:1) for administration to patients. The trial is
funded by the Medical Cannabis Bike Tour Foundation charity and is
scheduled to commence at University Hospital 12 de Octubre, on
September 5, 2023.
Denise Faltischek, Tilray’s Chief Strategy
Officer and Head of International Business, stated, "This
groundbreaking trial is more than an opportunity for Tilray to
engage in medical research; it's a beacon of hope for patients
suffering from Glioblastoma. Our role in this initiative
exemplifies our commitment to medical research, leading us one step
closer to unlocking the full therapeutic potential of medical
cannabis."
Led by esteemed coordinating investigator
Dr. Juan Manuel Sepúlveda Sánchez from GEINO, the
clinical trial is a Phase I, open-label, multicenter, intrapatient
dose-escalation to evaluate the safety and profile of
Tilray Medical’s T10:C10 (THC+CBD) extract, in
conjunction with temozolomide and radiotherapy for newly-diagnosed
Glioblastoma patients.
While medical cannabis research has been an
ongoing mission towards patient treatment, this trial is unique
because it is the culmination of a 10-year civil society
collaboration between the scientific sector and the medical
cannabis community. According to Dr. Juan
Sepulveda, “Biological evidence has been accumulating for more
than 15 years that cannabinoids have anti-tumor activity in the
most aggressive brain tumors, glioblastomas. However, no clinical
trials have been conducted to prove this hypothesis in patients.
With this clinical trial, we can finally study the effect of
cannabinoids on tumors that have not received active treatment.
With this trial, we are helping to give our patients a new option,
but also to open a therapeutic avenue. The trial is the result of a
collaboration between civil society through the Medical Cannabis
Bike Tour, an emerging pharmaceutical company and clinical
scientists.”
In 2013, the Medical Cannabis Bike
Tour began raising funds to support the work of the
Complutense Madrid University team. Guided by Dr.
Manuel Guzmán and Dr.
Guillermo Velasco, the team at Cannabinoid
Signalling Group was researching the effects of
cannabinoids on cancer cells and the potential as a glioblastoma
treatment. Today, with proceeds from the Medical Cannabis Bike
Tour founded by Luc Krol from the
Netherlands-based cannabis genetics seed bank, Paradise Seeds, the
Medical Bike Tour Foundation mobilized the European cannabis
community. It attracted significant sponsorship from the industry
over the course of five events held in different European countries
who were advocates for the impact of medical cannabis and its
benefits. As a result, Luc Krol passionately adds, “The world was
very different when we began the Medical Cannabis Bike Tour 10
years ago. We believed in the outstanding work of doctors including
Dr. Guzman and Velasco and their team and asked the cannabis
community for their support. The fact that the Medical Cannabis
Bike Tour can now independently fund a clinical trial in the name
of science, is amazing thanks to the sponsors and riders who made
it happen. We hope this trial will reflect the hope illuminated by
the scientific research for the participants involved.”
Tilray Medical’s mission is to continue
transforming lives and fostering dignity for patients in need
through access to medical cannabis, and today is a leading provider
of EU-GMP certified medical cannabis products in 20 countries with
a comprehensive portfolio of THC and CBD products. Tilray has
supported medical trials globally, across Europe, Canada, the
United States, Australia, and Latin America, studying the efficacy
of medical cannabis as a treatment for indications including
pediatric epilepsy, refractory pediatric epilepsy, cancer-induced
nausea and vomiting, HIV, essential tremor, breast cancer
disorders, post-traumatic stress disorder, and alcohol use
disorders.
About Tilray
Medical Tilray Medical is dedicated to transforming
lives and fostering dignity for patients in need through safe and
reliable access to a global portfolio of medical cannabis brands,
including Tilray, Aphria, Broken Coast, Symbios and Navcora. Tilray
grew from being one of the first companies to become an approved
licensed producer of medical cannabis in Canada to building the
first GMP-certified cannabis production facilities in Europe, first
in Portugal and later in Germany. Today, Tilray Medical is one of
the largest suppliers of medical cannabis to patients, physicians,
hospitals, pharmacies, researchers, and governments, in 20
countries and across five continents.
For more information on Tilray Medical, visit
Tilray Medical Europe, Tilray Medical Canada, and Tilray
Medical Australia-New Zealand.
About Tilray Brands
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY),
is a leading global cannabis-lifestyle and consumer packaged goods
company with operations in Canada, the United States, Europe,
Australia, and Latin America that is changing people's lives for
the better – one person at a time. Tilray Brands delivers on this
mission by inspiring and empowering the worldwide community to live
their very best life and providing access to products that meet the
needs of their mind, body, and soul while invoking wellbeing.
Patients and consumers trust Tilray Brands to deliver a cultivated
experience and health and wellbeing through high-quality,
differentiated brands and innovative products. A pioneer in
cannabis research, cultivation, and distribution, Tilray’s
unprecedented production platform supports over 20 brands in over
20 countries, including comprehensive cannabis offerings,
hemp-based foods, and craft beverages.
For more information on how we open a world of wellbeing,
visit www.Tilray.com.
Cautionary Statement Concerning
Forward-Looking Statements Certain statements in this
press release constitute forward-looking information or
forward-looking statements (together, “forward-looking statements”)
under Canadian securities laws and within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, that are intended
to be subject to the “safe harbor” created by those sections and
other applicable laws. Forward-looking statements can be identified
by words such as “forecast,” “future,” “should,” “could,” “enable,”
“potential,” “contemplate,” “believe,” “anticipate,” “estimate,”
“plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and
the negative of these terms or similar expressions, although not
all forward-looking statements contain these identifying words.
Certain material factors, estimates, goals, projections or
assumptions were used in drawing the conclusions contained in the
forward-looking statements throughout this communication.
Forward-looking statements include statements
regarding our intentions, beliefs, projections, outlook, analyses
or current expectations. Many factors could cause actual results,
performance or achievement to be materially different from any
forward-looking statements, and other risks and uncertainties not
presently known to the Company or that the Company deems immaterial
could also cause actual results or events to differ materially from
those expressed in the forward-looking statements contained herein.
For a more detailed discussion of these risks and other factors,
see the most recently filed annual information form of the Company
and the Annual Report on Form 10-K (and other periodic reports
filed with the SEC) of the Company made with
the SEC and available on EDGAR. The forward-looking
statements included in this communication are made as of the date
of this communication and the Company does not undertake any
obligation to publicly update such forward-looking statements to
reflect new information, subsequent events or otherwise unless
required by applicable securities laws.
Contacts:
Tilray Brands:Berrin Nooratanews@tilray.com
InvestorsRaphael
Gross203-682-8253Raphael.Gross@icrinc.com
Medical Cannabis Bike Tour Foundation
press@medicalcannabis-biketour.com
Tilray Brands (TG:2HQ)
過去 株価チャート
から 8 2024 まで 9 2024
Tilray Brands (TG:2HQ)
過去 株価チャート
から 9 2023 まで 9 2024